Market Overview

Goldman's Specialty Pharma Pair Trade: Sidelined On Endo, Bearish On Mallinckrodt

Goldman's Specialty Pharma Pair Trade: Sidelined On Endo, Bearish On Mallinckrodt
Related ENDP
Benzinga's Top Upgrades, Downgrades For November 9, 2018
80 Biggest Movers From Yesterday
Managers Of This Fund Like The Outlook For Small-Cap Stocks (Investor's Business Daily)
The Daily Biotech Pulse: Mallinckrodt FDA Verdict, European Cheer For Bristol-Myers Squibb, Morphosys Clinches Licensing Deal
The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results
Mallinckrodt Plc (MNK) Presents at Jefferies London Healthcare Broker Conference Call (Transcript) (Seeking Alpha)

The biotech sector has seen some year-to-date strength, as reflected by the nearly 11-percent advance in the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB). The upward momentum became more pronounced in late June.

Against this backdrop, a Goldman Sachs analyst is recommending a pair trade in the specialty pharma subsector.

The Analyst

Analyst Dana Flanders upgraded Endo International PLC (NASDAQ: ENDP) from Sell to Neutral and increased the price target from $14 to $15.

The analyst downgraded Mallinckrodt PLC (NYSE: MNK) from Neutral to Sell and upped the price target from $27 to $28.

The Thesis

The specialty pharma subsector has outperformed the S&P 500 Index since May 1 in the wake of the first-quarter reporting season and improving fundamentals, Flanders said in a Tuesday note. (See his track record here.)

The group is generally poised to continue to meet or beat 2018 guidance despite mixed pipeline progress and low innovation relative to other therapeutic subsectors, the analyst said. 

Endo's Progress Encouraging, But Valuation Stretched

The progress Endo has made in its base business against a stabilizing pricing environment is encouraging, Flanders said. The analyst said he expects 2019 to be a strong launch year for the company.

Although Endo's valuation appears stretched in light of risks such as high-margin 505(b)2 product concentration and opioid uncertainty, Flanders said the risks are balanced against stronger operational performance and an improving generics environment.

Caution On Mallinckrodt

Mallinckrodt shares are trading well off their lows as Acthar trends stabilize. Goldman Sachs expects upside to consensus Acthar estimates for the second half of 2018.

The pipeline that includes VTS-270 and CPP-1X has risk, Flanders said. The analyst is cautious on Acthar into 2019 and in the long term due to the potential for the re-emergence of payor pressure and competitive threats.

Mallinckrodt has to effectively allocate capital to drive growth across its business, especially as its key products face competition beyond 2021, Flanders said. 

The Price Action

Endo shares were down 0.81 percent at $15.99 at the close Tuesday, while Mallinckrodt shares slid 2.91 percent to $32.04. 

Related Links: 

New Class of Migraine Drug Creates Four-Way Pharma Development Race

The Week Ahead In Biotech: Conferences, Clinical Trial Results, Earnings And IPOs

Latest Ratings for ENDP

Nov 2018Canaccord GenuityUpgradesHoldBuy
Oct 2018Cantor FitzgeraldMaintainsNeutralNeutral
Sep 2018Goldman SachsUpgradesSellNeutral

View More Analyst Ratings for ENDP
View the Latest Analyst Ratings

Posted-In: Dana FlandersAnalyst Color Biotech Upgrades Downgrades Price Target Analyst Ratings General Best of Benzinga


Related Articles (ENDP + IBB)

View Comments and Join the Discussion!

Latest Ratings

CPAImperial CapitalDowngrades68.0
PRMWImperial CapitalInitiates Coverage On18.0
TGTKeyBancInitiates Coverage On110.0
QCOMMorgan StanleyUpgrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

6 Stocks Moving In Tuesday's After-Hours Session

RBC Stays Bullish On Micron, Lowers Estimates To Reflect Tougher Memory Forecast